Celcuity's Phase 3 VIKTORIA-1 trial showed gedatolisib combined with fulvestrant, with or without palbociclib, doubled progression-free survival (PFS) to about 11 months in patients with HR+/HER2- advanced breast cancer harboring PIK3CA mutations, compared to alpelisib plus fulvestrant which had a PFS of 5.6 months. The gedatolisib triplet also achieved a higher objective response rate (48.9%) and longer duration of response than the comparator. Safety profiles were favorable with fewer treatment discontinuations. These results position gedatolisib as a potential new standard of care pending FDA approval, with commercial launch anticipated in Q3 2026.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
NVIDIA and Noetra Corp. are partnering to build Japan's first national AI infrastructure, the NVIDIA Vera Rubin AI factory, featuring 13,750 Vera CPUs and 27,500 Rubin GPUs. Supported by Japan's Ministry of Economy, Trade and Industry, this 140-megaw...
Flight searches from the UK to destinations along the path of the August 12, 2026 solar eclipse have surged, with increases up to 201% for Spain's Cantabrian Coast and over 100% for Reykjavik, Iceland. This eclipse is notable as the first visible tot...
Solana (SOL) has gained about 30% from its June low, trading around $78 and surpassing its 50-day EMA. The token's upward momentum is supported by increased speculative trading and a new SuperTrend buy signal, the first since October 2025. However, i...
